 VANCOUVER, British Columbia, May 11, 2021 GLOBE NEWSWIRE -- WPD Pharmaceuticals Inc. CSE: WBIOFSE: 8SV1 the Company or WPD a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of 6,730,036 20,394,049.68 PLN from the Polish National Center for Research and Development NCRD, for the development of Annamycin, the Companys drug candidate used in the treatment of Acute Myeloid Leukemia AML. 